Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 15 Feb 2022
Senate confirms Califf as FDA chief in tight vote
15 February 2022 - The narrow 50-46 decision underscored the divisions on both sides of the aisle over agency policies on ...
Posted by Michael Wonder on 15 Feb 2022
Pembrolizumab in combination with chemotherapy: significant additional benefit in advanced squamous cell carcinoma of the oesophagus
15 February 2022 - Those affected survived a median of 14 months compared to nine in the control group. However, an ...
Posted by Michael Wonder on 15 Feb 2022
N.J. Governor Murphy outlines plan to lower prescription drug prices
14 February 2022 - New Jersey Governor Phil Murphy is promoting a legislative package aimed at lower prescription drug costs ...
Posted by Michael Wonder on 15 Feb 2022
ICER publishes final evidence report and policy recommendations on tirzepatide for type 2 diabetes
15 February 2022 - Independent appraisal committee found that evidence is adequate to demonstrate a net health benefit of tirzepatide added ...
Posted by Michael Wonder on 15 Feb 2022
NICE recommends new diagnostic devices for men with suspected prostate cancer in draft guidance
15 February 2022 - Four new diagnostic devices for men with suspected prostate cancer, which reduce the chances of biopsy related ...
Posted by Michael Wonder on 15 Feb 2022
With no votes to spare, Senate advances Califf’s FDA nomination toward final vote
14 February 2022 - In a dramatically close procedural vote Monday night, the Senate voted 49-45 to advance Robert Califf’s ...
Posted by Michael Wonder on 15 Feb 2022
‘New hope’: breakthrough cystic fibrosis treatment to be listed on PBS
14 February 2022 - Health Minister Greg Hunt says the breakthrough treatment for cystic fibrosis, Trikafta, will soon be able ...
Posted by Michael Wonder on 14 Feb 2022
Novavax files for conditional marketing authorisation of COVID-19 Vaccine in Switzerland
14 February 2022 - Novavax today announced its submission to Swissmedic, the Swiss Agency for Therapeutic Products, for conditional marketing authorisation ...
Posted by Michael Wonder on 14 Feb 2022
Anxiety mounts for Australian patients as supply chain crunch hits another arthritis drug
14 February 2022 - Patients are reckoning with major shortages of a second rheumatoid arthritis drug in Australia, with manufacturing ...
Posted by Michael Wonder on 14 Feb 2022
Medscape awarded contract from FDA to develop educational programming focused on biosimilars
14 February 2022 - Medscape Education has been awarded a contract from the U.S. FDA for the development of an ...
Posted by Michael Wonder on 14 Feb 2022
Confirmation fight over Biden's FDA nominee comes to a head
14 February 2022 - An intense confirmation battle over Robert Califf, President Biden’s nominee to lead the FDA, is poised ...
Posted by Michael Wonder on 14 Feb 2022
New CGM device for Australians with diabetes
14 February 2022 - Australians with diabetes will now have access to the next generation Dexcom G6 Continuous Glucose Monitoring, ...
Posted by Michael Wonder on 14 Feb 2022
Peter paid $60,000 to boost his cancer survival chances, but others miss out
15 February 2022 - Some cancer patients are dipping into their superannuation to pay for treatments under a “two-tiered system” ...
Posted by Michael Wonder on 14 Feb 2022
Members of Congress ask CDC to cut cost of new HIV prevention drug
11 February 2022 - “Only by making Apretude free can we fulfill its promise to liberate millions of people, particularly LGBTQ+ ...
Posted by Michael Wonder on 14 Feb 2022
WHO prequalifies first monoclonal antibody - tocilizumab – to treat COVID-19
11 February 2022 - Aiming to increase access to recommended treatments for COVID-19, WHO today added tocilizumab, a monoclonal antibody, ...